The University of Southampton
University of Southampton Institutional Repository

Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene

Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene
Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor beta gene (PDGFRB). We used imatinib to treat a 49-year old man with atypical CMD in accelerated phase and the H4 (D10S170)-PDGFRB fusion gene. After 3 months of treatment, we observed grade 4 hematologic toxicity and a lack of response.
0390-6078
1263-1264
Bastie, J.N.
a65e2f88-51f5-4320-afca-2ff5141d55a0
Garcia, I.
945da173-3918-4859-868f-5a8053844669
Terre, C.
4246a2cc-4153-426e-86b7-6580c09a884f
Cross, N.C.
f87650da-b908-4a34-b31b-d62c5f186fe4
Mahon, F.X.
53c8ef41-85b4-4cbf-b148-8eb6894180a3
Castaigne, S.
9ee25f29-5a4e-47db-8ce3-3a886d088ea7
Bastie, J.N.
a65e2f88-51f5-4320-afca-2ff5141d55a0
Garcia, I.
945da173-3918-4859-868f-5a8053844669
Terre, C.
4246a2cc-4153-426e-86b7-6580c09a884f
Cross, N.C.
f87650da-b908-4a34-b31b-d62c5f186fe4
Mahon, F.X.
53c8ef41-85b4-4cbf-b148-8eb6894180a3
Castaigne, S.
9ee25f29-5a4e-47db-8ce3-3a886d088ea7

Bastie, J.N., Garcia, I., Terre, C., Cross, N.C., Mahon, F.X. and Castaigne, S. (2004) Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. Haematologica, 89 (10), 1263-1264.

Record type: Article

Abstract

Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor beta gene (PDGFRB). We used imatinib to treat a 49-year old man with atypical CMD in accelerated phase and the H4 (D10S170)-PDGFRB fusion gene. After 3 months of treatment, we observed grade 4 hematologic toxicity and a lack of response.

Full text not available from this repository.

More information

Published date: 2004

Identifiers

Local EPrints ID: 24621
URI: https://eprints.soton.ac.uk/id/eprint/24621
ISSN: 0390-6078
PURE UUID: a0c02ed7-8852-48ea-8bb3-458332eafb24
ORCID for N.C. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 03 Apr 2006
Last modified: 06 Jun 2018 12:49

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×